TRAVERE THERAPEUTICS, INC. Long-term Purchase Commitment, Amount
TRAVERE THERAPEUTICS, INC. (TVTX) reported Long-term Purchase Commitment, Amount of $22.10 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermPurchaseCommitmentAmount · last filed 2023-11-07
- TRAVERE THERAPEUTICS, INC. long-term purchase commitment, amount for the quarter ending 2023-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. long-term purchase commitment, amount for the quarter ending 2023-06-30 was -$14.20M.
- TRAVERE THERAPEUTICS, INC. long-term purchase commitment, amount for the quarter ending 2023-03-31 was $36.30M.
- TRAVERE THERAPEUTICS, INC. long-term purchase commitment, amount for fiscal 2022 was $36.30M.
| Period end | Long-term Purchase Commitment, Amount 3 month | Long-term Purchase Commitment, Amount 6 month | Long-term Purchase Commitment, Amount 9 month | Long-term Purchase Commitment, Amount 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$14.20M derived: sum of 2 quarters · filed 2023-11-07 | $22.10M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$14.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $22.10M 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $36.30M 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $36.30M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |